The Medical Letter on Drugs and Therapeutics
Low-Dose Diclofenac (Zorvolex) for Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Zorvolex (Iroko), a low-dose oral formulation of the relatively COX-2 selective NSAID diclofenac, for treatment of mild-to-moderate acute pain in adults.

Zorvolex is available as 18- and 35-mg capsules. Other oral formulations of diclofenac include immediate-release, extended-release, and enteric-coated tablets and capsules in strengths ranging from 25 to 100 mg. Diclofenac is also available topically as a transdermal patch (Flector), a gel (Voltaren Gel), and a solution (Pennsaid).

THE NEW FORMULATION — Each capsule of Zorvolex contains diclofenac as submicron particles. The reduction in particle size increases surface area, leading to faster dissolution and absorption of the drug. A single-dose crossover study compared the new 35-mg formulation of diclofenac to diclofenac potassium 50 mg in healthy subjects. Taken without food, Tmax was about ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Low-Dose Diclofenac (Zorvolex) for Pain
Article code: 1437c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian